Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MomeGalen vs Ecural in Plaque Psoriasis
2024-511583-82-00Phase 3Completed
- Sponsor
- GALENpharma GmbH
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of mometasone in plaque psoriasis (3 arms), sponsored by GALENpharma GmbH. Primary endpoint: Primary efficacy endpoint: percent change from baseline in TSS on Day 22. Started Aug 2024; status: completed.
02
Drugs
mometasone
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-511583-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511583-82-00.